Pricing Log in Create free account
Friday 6 November 2026 Export PEN’s income statement to Excel — free account

Penumbra, Inc.

PEN Healthcare Medical Devices

Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.

Revenue
+15.6%
EPS
−8.29%
Free cash flow
−37.2%
Total debt
−10.3%

Quarter to September 2026, against a year earlier

320.08 1.03 −0.32%
Market cap
$12.7B
P/E
80.3×
Fwd P/E
68.7×
Dividend yield
—
F-score
8/9
Altman Z
20.17
Beneish M
−2.48
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Penumbra, Inc. (PEN) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Penumbra, Inc. (PEN) trades at a EV/EBITDA of 57.3×. Over the past ten years it has ranged from 0.0× (December 2022) to 3,457× (November 2018); the current reading is higher than 31% of that period. That is above the Medical Devices industry median of 11.5× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 56.0× (79.15%)
FY2024 269× 196.37%
FY2023 90.6× (66.44%)
FY2022 270× (76.73%)
FY2021 1,160× —
FY2020 0.0× —
FY2019 99.7× (86.65%)
FY2018 747× 33.61%
FY2017 559× (40.37%)
FY2016 938× 1,035.50%

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 56.8× (1.49%)
Jun 2026 57.6× (4.33%)
Mar 2026 60.3× 7.60%
Dec 2025 56.0× 12.70%
43 more quarters

Against its own ten years

Low 0.0× High 3,457×
Ten-year median 116×
Current reading's percentile 31

EV/EBITDA against peers

Company EV/EBITDA
BIO Bio-Rad Laboratories, Inc. compare n/m
GKOS Glaukos Corporation compare n/m
TXG 10x Genomics compare n/m
BIO.B Bio-Rad Laboratories, Inc. compare n/m
SNN Smith & Nephew SNATS, Inc. compare 6.5×
GMED Globus Medical, Inc. compare 11.9×
PODD Insulet Corporation compare 16.1×
PEN Penumbra, Inc. 57.3×
BRKR Bruker Corporation compare 66.0×
Medical Devices industry median 11.5×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on PEN